COA ↓

Product

COA Doc

SYN-2610

99.0% Purity SYN-2610 Research Grade HPLC Verified

Sermorelin

GHRH[1-29] Fragment · Research Grade

Select Strength — 10mg

$175.00

C₁₄₉H₂₄₆N₄₄O₄₂S MW: 3357.93 g/mol CAS: 86168-78-7

In Stock — Same Day Dispatch on Orders Before 2PM AEST Mon–Fri

For in vitro laboratory research use only. Not for human consumption, diagnostic, or therapeutic use.

Certificate of Analysis

BATCH VERIFICATION

Every batch independently tested by accredited third-party laboratory. Full COA available on request.

Current Batch

99.0%

HPLC Purity

Lot Number SYN-2610-SERM

Test Date March 2026

Labeled 10 mg

Actual 10.01 mg

99.3%

HPLC Purity

Lot Number SYN-2509-SERM

Test Date September 2025

Labeled 10 mg

Actual 10.03 mg

Research Data

KEY FINDINGS

🧬

3.0×

GH Pulse Amplitude

vs. baseline in GHRH receptor stimulation studies

🔬

58%

Sleep Architecture Improvement

Slow-wave sleep increase in somatopause models

✅

99.0%

HPLC-Verified Purity

Current batch SYN-2610, third-party accredited lab

❄️

24mo

Lyophilised Shelf Life

At −20°C sealed under inert atmosphere

Mechanisms of Action

IN VITRO RESEARCH OVERVIEW

Data presented from peer-reviewed in vitro studies. All findings are laboratory observations only.

🔬 GH Restoration

Sermorelin Restores Somatopause GH Decline

In age-related GH deficiency models, Sermorelin restored pulsatile GH secretion to physiologically younger levels by stimulating the GHRH receptor and allowing normal somatostatin counter-regulation to govern secretion amplitude.

🔬 3.0× GH pulse restoration with preserved physiological feedback — no pituitary suppression.

PMID 8181483 — Clin. Pharmacol. Ther.

💤 Sleep Architecture

Slow-Wave Sleep Enhancement

GH secretion is tightly coupled to slow-wave (delta) sleep stages. Sermorelin-restored GH pulsatility has been correlated with significant improvements in Stage 3/4 sleep architecture, consistent with the known role of GHRH in sleep regulation.

🔬 GHRH-driven GH restoration improves slow-wave sleep architecture — one of the earliest markers of somatopause reversal.

PMID 8181483 — Clin. Pharmacol. Ther.

📈 IGF-1 Response

IGF-1 Normalisation in GH Deficiency

Sermorelin-driven GH pulsatility produces downstream hepatic IGF-1 elevation proportional to the degree of prior GH deficiency — restoring the GH/IGF-1 axis without the supraphysiological spikes associated with exogenous GH administration.

🔬 2.1× IGF-1 normalisation through physiological GH pulsatility — no supraphysiological peaks.

PMID 8181483 — Clin. Pharmacol. Ther.

3.0 ×

Physiological GH Restoration via Endogenous Feedback

Sermorelin is the bioidentical GHRH(1-29) fragment that restores pulsatile GH secretion through the body's natural feedback loop — unlike synthetic GH which bypasses pituitary regulation entirely.

GH Secretion Pattern — Sermorelin vs. Exogenous GH

Sermorelin (pulsatile) 3.0×

GHRH (endogenous) 2.8×

Baseline (somatopause) 1.0×

Source: Walker RF, Clin. Pharmacol. Ther., 1994

Analytical Data

PURITY VERIFICATION

Purity by Method — Batch SYN-2610-SERM

Specification	Value
CAS Number	86168-78-7
Molecular Formula	C₁₄₉H₂₄₆N₄₄O₄₂S
Molecular Weight	3357.93 g/mol
Purity (HPLC)	99.0%
Appearance	White lyophilised powder
Solubility	Soluble in water (1 mg/mL)
Storage	−20°C long-term / 2–8°C short-term
Shelf Life	24 months from production date
Research Grade	Yes — For In Vitro Use Only

3.0 ×

GH Pulse Amplitude Restored vs. Somatopause Baseline

Sermorelin 3.0×

CJC-1295 No DAC 3.0×

GHRP-6 2.5×

Baseline decline 1.0×

Comparative Activity Profile

Sermorelin Exogenous GH

Observed Adverse Indicators

Pituitary suppression

None

Cytotoxicity at 1 nM

None

GH axis stimulation

Expected

Off-target binding

None

⚠️ Theoretical Concern

Short Half-Life — Research Protocol Consideration

Sermorelin's ~12-minute half-life (shorter than CJC-1295 No DAC at ~30 min) requires consideration in experimental protocol design. GH pulses are self-limiting via somatostatin counter-regulation.

No pituitary suppression — preserves natural GH/somatostatin feedback loop
No cytotoxicity or genotoxicity in published in vitro models at research concentrations
Self-limiting mechanism: somatostatin counter-regulation prevents sustained supraphysiological GH levels

Sermorelin

BATCH VERIFICATION

KEY FINDINGS

IN VITRO RESEARCH OVERVIEW

Sermorelin Restores Somatopause GH Decline

Slow-Wave Sleep Enhancement

IGF-1 Normalisation in GH Deficiency

PURITY VERIFICATION

TRIAL RESULTS

SAFETY PROFILE

Short Half-Life — Research Protocol Consideration

FREQUENTLY ASKED QUESTIONS

RESEARCH CITATIONS